Entero Therapeutics, Inc.
ENTO
$1.91
$0.010.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 88.67% | -122.62% | -198.43% | 24.84% | -110.25% |
| Total Depreciation and Amortization | -- | -- | -569.86% | -82.19% | 383.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -100.00% | 101.30% | 6,600.88% | -43.44% | 1,575.14% |
| Change in Net Operating Assets | 537.86% | -30.35% | 183.07% | 304.08% | -86.70% |
| Cash from Operations | 98.41% | 78.15% | 95.01% | 44.51% | -24.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 100.00% | -- | -- |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -15.70% | -6.21% |
| Issuance of Common Stock | -- | -- | -100.00% | -68.77% | -58.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -79.28% | -100.73% | -71.18% | -64.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.02% | 57.63% | -148.47% | -114.38% | -234.31% |